← Back to home

REFRACTORY EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED

Clinical trials for REFRACTORY EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear

Sign up with your email to follow new studies for REFRACTORY EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New bridge to a cancer cure: drug combo aims to get more patients to Life-Saving CAR-T

Disease control Recruiting now

This study is testing a two-drug combination (golcadomide and rituximab) as a 'bridging therapy' for adults with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The goal is to control the cancer and improve patients' health so they can qualify fo…

Matched conditions: REFRACTORY EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED

Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control

Last updated Mar 27, 2026 12:38 UTC

REFRACTORY EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED

Get alerted when new REFRACTORY EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear

New bridge to a cancer cure: drug combo aims to get more patients to Life-Saving CAR-T